O	0	6	Safety
O	7	14	results
O	15	19	from
O	20	21	a
O	22	27	phase
O	28	31	III
O	32	37	study
O	38	39	(
O	39	47	TURANDOT
O	48	53	trial
O	54	56	by
O	57	62	CECOG
O	62	63	)
O	64	66	of
O	67	72	first
O	72	73	-
O	73	77	line
B-intervention	78	89	bevacizumab
I-intervention	90	92	in
I-intervention	93	104	combination
I-intervention	105	109	with
I-intervention	110	122	capecitabine
O	123	125	or
B-control	126	136	paclitaxel
O	137	140	for
O	141	144	HER
O	144	145	-
O	145	146	2
O	146	147	-
O	147	155	negative
O	156	163	locally
O	164	173	recurrent
O	174	176	or
O	177	187	metastatic
O	188	194	breast
O	195	201	cancer
O	201	202	.

O	203	205	We
O	206	212	report
O	213	219	safety
O	220	224	data
O	225	229	from
O	230	231	a
O	232	242	randomised
O	242	243	,
O	244	249	phase
O	250	253	III
O	254	259	study
O	260	261	(
O	261	266	CECOG
O	266	267	/
O	267	269	BC
O	269	270	.
O	270	271	1
O	271	272	.
O	272	273	3
O	273	274	.
O	274	277	005
O	277	278	)
O	279	289	evaluating
O	290	295	first
O	295	296	-
O	296	300	line
O	301	312	bevacizumab
O	313	317	plus
O	318	328	paclitaxel
O	329	331	or
O	332	344	capecitabine
O	345	348	for
O	349	356	locally
O	357	366	recurrent
O	367	369	or
O	370	380	metastatic
O	381	387	breast
O	388	394	cancer
O	394	395	.

O	396	404	Patients
O	405	409	aged
B-age	410	411	â‰¥
I-age	411	413	18
I-age	414	419	years
O	420	424	with
O	425	430	human
O	431	440	epidermal
O	441	447	growth
O	448	454	factor
O	455	463	receptor
O	463	464	-
O	464	465	2
O	465	466	-
O	466	474	negative
O	475	481	breast
O	482	496	adenocarcinoma
O	497	501	were
O	502	512	randomised
O	513	515	to
O	516	519	Arm
O	520	521	A
O	521	522	:
O	523	534	bevacizumab
O	535	537	10
O	538	540	mg
O	540	541	/
O	541	543	kg
O	544	548	days
O	549	550	1
O	551	554	and
O	555	557	15
O	557	558	;
O	559	569	paclitaxel
O	570	572	90
O	573	575	mg
O	575	576	/
O	576	577	m
O	577	578	(
O	578	579	2
O	579	580	)
O	581	585	days
O	586	587	1
O	587	588	,
O	589	590	8
O	590	591	,
O	592	595	and
O	596	598	15
O	598	599	,
O	600	605	every
O	606	607	4
O	608	613	weeks
O	613	614	;
O	615	617	or
O	618	621	Arm
O	622	623	B
O	623	624	:
O	625	636	bevacizumab
O	637	639	15
O	640	642	mg
O	642	643	/
O	643	645	kg
O	646	649	day
O	650	651	1
O	651	652	;
O	653	665	capecitabine
O	666	670	1000
O	671	673	mg
O	673	674	/
O	674	675	m
O	675	676	(
O	676	677	2
O	677	678	)
O	679	680	b
O	680	681	.
O	681	682	i
O	682	683	.
O	683	684	d
O	684	685	.
O	685	686	,
O	687	691	days
O	692	693	1
O	693	694	-
O	694	696	14
O	696	697	,
O	698	703	every
O	704	705	3
O	706	711	weeks
O	711	712	,
O	713	718	until
O	719	726	disease
O	727	738	progression
O	738	739	,
O	740	752	unacceptable
O	753	761	toxicity
O	762	764	or
O	765	772	consent
O	773	783	withdrawal
O	783	784	.

O	785	786	A
O	787	791	post
O	792	795	hoc
O	796	803	interim
O	804	810	safety
O	811	819	analysis
O	820	828	included
B-total-participants	829	832	561
O	833	841	patients
O	842	843	(
O	843	846	Arm
O	847	848	A
O	848	849	:
B-intervention-participants	850	853	284
O	853	854	,
O	855	858	Arm
O	859	860	B
O	860	861	:
B-control-participants	862	865	277
O	865	866	)
O	866	867	.

O	868	871	The
O	872	880	regimens
O	881	893	demonstrated
O	894	901	similar
O	902	913	frequencies
O	914	916	of
O	917	920	all
O	920	921	-
O	921	926	grade
O	927	930	and
O	931	938	serious
O	939	946	adverse
O	947	953	events
O	954	955	(
O	955	959	SAEs
O	959	960	)
O	960	961	,
O	962	965	but
O	966	975	different
O	976	982	safety
O	983	991	profiles
O	991	992	.

B-outcome	993	1002	Treatment
I-outcome	1002	1003	-
I-outcome	1003	1010	related
I-outcome	1011	1017	events
O	1018	1026	occurred
O	1027	1029	in
B-iv-bin-percent	1030	1032	85
I-iv-bin-percent	1032	1033	.
I-iv-bin-percent	1033	1034	2
I-iv-bin-percent	1034	1035	%
O	1036	1037	(
O	1037	1040	Arm
O	1041	1042	A
O	1042	1043	)
O	1044	1047	and
B-cv-bin-percent	1048	1050	78
I-cv-bin-percent	1050	1051	.
I-cv-bin-percent	1051	1052	0
I-cv-bin-percent	1052	1053	%
O	1054	1055	(
O	1055	1058	Arm
O	1059	1060	B
O	1060	1061	)
O	1062	1064	of
O	1065	1073	patients
O	1073	1074	.

B-outcome	1075	1082	Fatigue
O	1083	1086	was
O	1087	1091	most
O	1092	1098	common
O	1099	1101	in
O	1102	1105	Arm
O	1106	1107	A
O	1108	1109	(
B-iv-bin-percent	1109	1111	30
I-iv-bin-percent	1111	1112	.
I-iv-bin-percent	1112	1113	6
I-iv-bin-percent	1113	1114	%
O	1115	1121	versus
B-cv-bin-percent	1122	1124	23
I-cv-bin-percent	1124	1125	.
I-cv-bin-percent	1125	1126	5
I-cv-bin-percent	1126	1127	%
O	1128	1131	Arm
O	1132	1133	B
O	1133	1134	)
O	1134	1135	,
O	1136	1139	and
B-outcome	1140	1144	hand
I-outcome	1144	1145	-
I-outcome	1145	1149	foot
I-outcome	1150	1158	syndrome
I-outcome	1159	1160	(
I-outcome	1160	1163	HFS
I-outcome	1163	1164	)
O	1165	1169	most
O	1170	1176	common
O	1177	1179	in
O	1180	1183	Arm
O	1184	1185	B
O	1186	1187	(
B-cv-bin-percent	1187	1189	49
I-cv-bin-percent	1189	1190	.
I-cv-bin-percent	1190	1191	5
I-cv-bin-percent	1191	1192	%
O	1193	1199	versus
B-iv-bin-percent	1200	1201	2
I-iv-bin-percent	1201	1202	.
I-iv-bin-percent	1202	1203	5
I-iv-bin-percent	1203	1204	%
O	1205	1208	Arm
O	1209	1210	A
O	1210	1211	)
O	1211	1212	.

B-outcome	1213	1222	Diarrhoea
O	1223	1224	(
O	1224	1227	Arm
O	1228	1229	A
O	1229	1230	:
B-iv-bin-percent	1231	1232	0
I-iv-bin-percent	1232	1233	.
I-iv-bin-percent	1233	1234	4
I-iv-bin-percent	1234	1235	%
O	1235	1236	,
O	1237	1240	Arm
O	1241	1242	B
O	1242	1243	:
B-cv-bin-percent	1244	1245	1
I-cv-bin-percent	1245	1246	.
I-cv-bin-percent	1246	1247	4
I-cv-bin-percent	1247	1248	%
O	1248	1249	)
O	1250	1253	and
B-outcome	1254	1263	pulmonary
I-outcome	1264	1272	embolism
O	1273	1274	(
O	1274	1277	Arm
O	1278	1279	A
O	1279	1280	:
B-iv-bin-percent	1281	1282	0
I-iv-bin-percent	1282	1283	.
I-iv-bin-percent	1283	1284	7
I-iv-bin-percent	1284	1285	%
O	1285	1286	,
O	1287	1290	Arm
O	1291	1292	B
O	1292	1293	:
B-cv-bin-percent	1294	1295	1
I-cv-bin-percent	1295	1296	.
I-cv-bin-percent	1296	1297	1
I-cv-bin-percent	1297	1298	%
O	1298	1299	)
O	1300	1304	were
O	1305	1308	the
O	1309	1313	most
O	1314	1324	frequently
O	1325	1333	reported
O	1334	1338	SAEs
O	1338	1339	.

O	1340	1345	These
O	1346	1354	findings
O	1355	1358	are
O	1359	1361	in
O	1361	1362	-
O	1362	1366	line
O	1367	1371	with
O	1372	1378	safety
O	1379	1383	data
O	1384	1387	for
O	1388	1399	bevacizumab
O	1400	1404	plus
O	1405	1415	paclitaxel
O	1416	1418	or
O	1419	1431	capecitabine
O	1431	1432	,
O	1433	1441	reported
O	1442	1444	in
O	1445	1453	previous
O	1454	1459	phase
O	1460	1463	III
O	1464	1470	trials
O	1470	1471	.
